Research
    Xia Liangping
    Title Chief physician, doctoral advisor and Associate Chief for Department of Comprehensive Treatment
    Profile

    Prof. Xia Liangping specializes in formulation and analysis of comprehensive treatment strategies for common tumors, treatment and research of medical oncology, such as common intestinal cancer and lung cancer, as well as health care and management of VIP patients.

    Work experience
    1994-1996: Department of Surgery in the First Affiliated Hospital, Anhui Medical University;

    2002-present: Department of Comprehensive Treatment, Sun Yat-sen University Cancer Center

    Email
    Phone
    Research Interest(s)
    Education

    1989-1994: Department of Medicine, Anhui Medical University;
    1996-1999: The First Affiliated Hospital, Sun Yat-sen University (master's program);
    1999-2002: Sun Yat-sen University Cancer Center (doctoral program).

    Publications

    1. Chen ZY, He WZ, Peng LX, Jia WH, Guo RP, Xia LP, Qian CN.A prognostic classifier consisting of 17 circulating cytokines is a novel predictorLiao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2014;7:1415-22.
    3. Jiang C, Liao FX, Rong RM, Yang Q, Yin CX, He WZ, Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP. Efficacy of Taxane-Based Regimens in a First-line Setting for Recurrent and/or Metastatic Chinese Patients with Esophageal Cancer. Asian Pac J Cancer Prev. 2014;15(13):5493-8.
    4. He  WZ, Guo GF, Yin CX, Jiang C, Wang F, Qiu HJ, Chen XX, Rong RM, Zhang B, Xia LP. γ-Glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer. Colorectal Dis. 2013 Aug;15(8):e443-52.. 
    5. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, Chen X, Rong R, Zhang B, Xia L. Initial Neutrophil Lymphocyte Ratio Is Superior To Platelet Lymphocyte Ratio As An Adverse Prognostic and Predictive Factor In Metastatic Colorectal Cancer. Medical Oncology. 2013 Mar;30(1):439.
    6. Wang F, He W, Qiu H, Wang X, Guo G, Chen X, Rong Y, Zhou F, Yin C, Yuan Z, Xia L. Lymph Node Ratio and pN Staging Show  FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352. 
    7. Guo GF, Jiang WQ, Zhang B, Cai YC, Xu RH, Wang F, Chen XX, Xia LP. Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy in advanced colorectal cancer. World J Gastroenterol. 2011; 17(43): 4839-4846.
    8. Zhou FF, Yan M, Guo GF, Wang F, Qiu HJ, Zheng FM, Zhang Y, Liu Q, Zhu XF, Xia LP*.Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity correlates with increase of Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 2011 Dec;28(4):1302-7.
    9. Xia LP, Qiu HJ, Chen XX, Hu PL, Guo GF, Wang F, Zhou FF, He WZ, Zhang B, Zhang L. Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Med Oncol. 2011 Dec;28 Suppl 1:570-6.
    10. Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F.Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol. 2011 Dec;28 Suppl 1:197-203.
    11. Zhou FF, Xia LP, Guo GF, Wang X, Yuan ZY, Zhang B, Wang F. Changes in Therapeutic Strategies in Chinese Male Patients with Breast Cancer: 40 Years of Experience in a Single Institute. Breast. 2010;19(6):450-5.
    12. Xia LP, Zhou FF, Guo GF, Wang F, Wang X, Yuan ZY, Zhang B. Chinese Female Breast Cancer Patients Show A Better Overall Survival Than Their Male Counterparts. Chinese Medicine Journal. 2010;123(17):2347-2352.
    13. Yin CX, Jiang C, Liao FX, Rong RM, He WZ,Cai XY, Guo GF, Qiu HJ Chen XX, Zhang B, Xia LP.The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting. Chinese-German Journal of Clinical Oncology. 2014;13(4): 169-173.
    14. Zhang B, He WZ, Zhou FF, Guo GF, Jiang C, Yin CX,  Chen XX, Qiu HJ, Rong RM, Xia LP. A Potential Administration-time Dependent Effect of Bevacizumab in Improving Overall Survival and Increasing Metastasis in Metastatic Colorectal Cancer. Chemotherapy,2013, 2:108. doi:10.4172/2167-7700.1000108
    15. Qiu HJ, He WZ, Yin CX, Guo GF, Wang F, Zhou FF, Jiang C, Xia LP. The efficacy and its related issues of combination of bevacizumab and taxanes-based regimens in Chinese patients with metastatic breast cancer. Chinese-German Journal of Clinical Oncology. 2012;11(10): 585-591.
    16. Wang F, Guo GF, Qiu HJ, He WZ, Zhou FF , Chen XX, Hu PL, Zhang B, Yin CX, Zhang L, Xia LP. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biology & Medicine. 2012;9(1):38-43.
    17. Wang F, Guo GF, Qiu HJ, Chen XX, Hui PL, Zhou FF, He WZ, Zhang B, Xia LP. Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer. Clin Oncol Cancer Res. 2011; 8(4): 235–241
    18. Qiu HJ, He WZ, Chen XX, Guo GF, Wang F, Zhou FF, Xia LP. The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. Chinese-German Journal of Clinical Oncology.2011;10(11): 621-625.
    19. Zhou FF,  Huang R, Jiang J, Wang F,  He WZ, Guo GF, Xia LP. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer. Chinese-German Journal of Clinical Oncology.2011;10(6): 311-316.
    20. Qiu HJ, Wang F, Guo GF, Zhou FF, He WZ, Xia LP. Non-platinum doublets versus single agents in non-small cell lung cancer (NSCLC) patients with elderly age and/or poor performance status: a meta-analysis. Chinese-German Journal of Clinical Oncology. 2011;10(3): 134-139.
    21. Wang F, Xia LP, Guo GF, Qiu HJ, Zhou FF, He WZ. The Pooled Analysis of Single Gemcitabine For Non-Small Cell Lung Cancer (NSCLC) Patients With Elderly Age. Chinese-German Journal of Clinical Oncology.2010;9(12):683-687.

    Guifang Guo
    Title Professor
    Profile

    Dr. Gui-Fang Guo is a Professor in the VIP Department of Sun Yat-sen University Cancer Center. She obtained his doctor's degree in Medicine at Sun Yat-sen University, P. R. China in 2010. Dr. Guo had been a high visiting scholar at Florida University from 2013 to 2014. She specialize in medical oncology, especially in gastrointestinal tumors and lung cancer.

    Email guogf@sysucc.org.cn
    Phone 86-20-87343455
    Research Interest(s)

    Clinical and basic research in medical oncology and translational medicine, especially in diagnosis and therapy for the gastrointestinal tumor.

    Education

    1993.09—1998.06: Undergraduate, Department of Clinical Medicine, Anhui Wannan Medical College

    2001.09-2004.06: Sun Yat-sen University Cancer Center (Master student)

    2007.09-2010.06: Sun Yat-sen University Cancer Center (PhD student)

    2013.08-2014.07: Senior visiting scholar (postdoctoral work), Florida University, USA

    Publications

    1. Guifang Guo*#( the First and corresponding author), Yixing Wang#, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang and Liangping Xia. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother cancer. 2019 Jul 12;7(1):179-191.

    2. Gui-Fang Guo*#( the First and corresponding author), Yi-Xing Wang#, Yi-Jun Zhang, Xiu-Xing Chen, Jia-Bin Lu, Hao-Hua Wang, Chang Jiang, Hui-Quan Qiu, Liang-Ping Xia. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. World J Gastroenterol. 2019 Apr 21;25(15):1840-1853.

    3. Guo G*#( the First and corresponding author), Chen X#, He W, Wang H, Wang Y, Hu P, Rong Y, Fan L, Xia L. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS One. 2018 Dec 4;13(12):e0208547.

    4. Haohua Wang#, Roujun Peng#, Xiuxing Chen, Rui Jia, Chunyue Huang, Yuanyuan Huang, Liangping Xia and Guifang Guo* (corresponding author).Effect of HK2, PKM2 and LDHA on Cetuximab efficacy  in metastatic colorectal cancer. Oncology Letters, 2018 Apr;15(4):5553-5560.

    5. Zheng Yan, BeiZhang, Yuan-Yuan Huang, Hui-Juan Qiu, Ping Chen, Gui-Fang Guo*( corresponding author). Involvement of autophagy inhibition in Brucea javanica oil emulsion induced colon cancer cell death. Oncology Letters 2015 (9):1425-1431, 2015.

    6. Xiuxing Chen#, Yanfeng Chen, Xiuyu Cai, Dongsheng Zhang, Lei Fan, Huijuan Qiu,  Bei Zhang, Guifang Guo*( corresponding author). Efficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta‑analysis. J Can Res Ther 2017;13:869-77.

    7. Guifang Guo*#( the First and corresponding author), Xiuxing Chen#, Xiuyu Cai, Yanfeng Chen, Haohua Wang, Lei Fan,Long Bai, Huijuan Qiu, Bei Zhang. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy. Transl Cancer Res 2019;8(4):1137-1147.

    8. Mai J#,  Zhong ZY#,  Guo GF#(co-first author),  Chen XX,  Xiang YQ,  Li X,  Zhang HL,  Chen YH,  Xu XL,  Wu RY,  Yu Y,  Li ZL,  Peng XD,  Huang Y,  Zhou LH,  Feng GK,  Guo X,  Deng R,  Zhu XF, Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promotetumorigenesis in nasopharyngeal carcinoma. Theranostics 2019 May 26;9(12):3541-3554 DOI:10.7150/thno.32908

    9. Fang Wang, Gui-fang Guo (co-first author), Hui-juan Qiu, Wen-zhuo He, Fei-fei Zhou, Xu-xian Chen, Pi-li Hu, Bei Zhang, Chen-xi Yin, Li Zhang, Liang-ping Xia*. Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung Cancer. Cancer Biol Med. 2012 Mar;9(1):38-43.

    10. Lin Yang; Zhenchong Xiong; Qiankun Xie; Wenzhuo He; Shousheng Liu; Pengfei Kong; Chang Jiang; Guifang Guo (co-corresponding author); Liangping Xia*. Prognostic value of total number of lymph nodes retrieved differs between left-sided colon cancer and right-sided colon cancer in stage III patients with colon cancer. BMC Cancer. 2018 May 11;18(1):558.

    11. Lin Yang; Zhenchong Xiong; Wenzhuo He; Kunqian Xie; Shousheng Liu; Pengfei Kong; Chang Jiang; Guifang Guo (co-corresponding author); Liangping Xia*. Proximal shift of colorectal cancer with increasing age in different ethnicities, Cancer Manag Res. 2018 Aug 15;10:2663-2673.

    12. W.-z. He; G.-f. Guo (co-first author); C.-x. Yin; C. Jiang; F. Wang; H.-j. Qiu; X.-x. Chen; R.-m. Rong; B. Zhang; L.-p. Xia*. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer, Colorectal Dis. 2013.4.26; 15(8): e443-452.

    14. Guo GF. Prognostic and predictive inflammation-based markers for advanced colorectal cancer of the elderly patients. Journal of Clinical Oncology. 2016;34(15):2.e15069

    15. Gui-fang Guo(#), Bei Zhang, Yu-chen Cai, Rui-hua Xu, Xu-xian Chen, Pei-li Hu,  Hui-juan Qiu, Fang Wang, Liang-ping Xia  Wen-qi Jiang. Autophagy-related Proteins Beclin-1 and LC3 Predicting Cetuximab Efficacy in Advanced Colorectal Cancer. World Journal of Gastroenterology. 2011 November 21;17(43):4741-4838.

    16. Gui-fang Guo(#), Yu-chen Cai, Bei Zhang, Rui-hua Xu, Hui-juan Qiu, Liang-ping Xia, Wen-qi Jiang, Pei-li Hu, Xu-xian Chen, Feifei Zhou, Fang Wang. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Medical Oncology. 2011 Dec;28 Suppl 1:S197-203. Epub 2010 Nov 17.

    Updated June 2020

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.